G-protein Coupled Receptors Market Size, Share, and Industry Analysis, By Type (Adhesion G Protein-coupled Receptors, Secretin Receptor, and Others), By Application (Disease Diagnosis, Drug Discovery & Development, and Others), By End-user (Pharmaceutical & Biotechnology Industry, Academic & Research Institutes, and Others), and Regional Forecast, 2026-2034

The global g-protein coupled receptors market size was valued at USD 4.90 billion in 2025. The market is projected to grow from USD 5.30 billion in 2026 to USD 10.04 billion by 2034, exhibiting a CAGR of 8.31% during the forecast period.

The global G-protein coupled receptors market is witnessing significant growth during the forecast period. The rise in research and development activities, such as high-throughput screening and drug discovery based on GPCRs in both academic and commercial sectors, is contributing to market growth. The market growth is also fueled by factors such as increasing demand for targeted therapies, advancements in drug discovery technologies, and the rise in the number of clinical trials focused on GPCR-targeted drugs. Additionally, a high influx of investment in the R&D sector also supports the market growth.

• For instance, in April 2021, Tectonic Therapeutics raised USD 80 million in a series A financing for the transformation of the discovery of novel G-protein coupled receptor (GPCR)-targeted therapies.

G-protein Coupled Receptors Market Driver

Increase in R&D Investments in Drug Discovery Based on GPCR Drives Market Growth

The global G-protein coupled receptors (GPCRs) market is experiencing substantial growth, primarily driven by the rise in R&D investments in the discovery of G-protein coupled receptor drugs. The GPCRs are involved in various cellular processes and are already targeted by many successful drugs. Due to such factors, pharmaceutical and biotechnology companies are heavily investing in research and development of novel GPCR-targeted therapeutics.

• For instance, in January 2024, St. Jude Children’s Research Hospital invested USD 13 million in new research to expand the understanding of G-protein coupled receptors (GPCR) in collaboration with the scientists at Columbia University, Duke University, and Stanford University.

Global Share of G-protein Coupled Receptor Drugs in Overall Drugs (in %), 2021

According to the data published in June 2024, in 2021, approximately 60% of the drugs were under development, and out of all the U.S. FDA-approved drugs, 36.0% of drugs target GPCRs.

G-protein Coupled Receptors Market Restraint

High Complexity of GPCR Signaling May Hinder Market Growth

The complexity of G-protein coupled receptor (GPCR) signaling pathways is a significant restraint in the G-protein coupled receptors market. This complexity arises from the intricate nature of GPCR interactions with multiple signaling molecules and their diverse functionalities. This type of complexity is challenging for drug development as it can be difficult to predict the effects of drugs on specific GPCRs.

• For instance, according to the data published by the British Pharmacological Society in 2025, the challenges in GPCR research include GPCR signaling complexity. 

G-protein Coupled Receptors Market Opportunity

Development of Novel GPCR-Targeting Drugs May Offer Growth Opportunities in Future

The development of novel drugs targeting G-protein coupled receptors (GPCRs) offers a substantial market opportunity. The rise in collaboration and partnerships between key players for the novel GPCR targeting drug development also provides lucrative growth opportunities. Additionally, the companies are actively focusing on developing novel drugs that target G-protein coupled receptors due to their involvement in various physiological processes and disease pathways, and advancements in drug discovery technologies. 

• For instance, in November 2024, Nxera Pharma and Antiverse entered into a partnership and licensing agreement to design novel G-protein coupled receptor-targeted antibody therapeutics by using generative AI.

Key Insights

The report covers the following key insights:

• Technological Advancements in GPCR-Targeted Drug Development
• New Product Launches, By Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

Segmentation

Analysis by Type

By type, the market is divided into adhesion G protein-coupled receptors, secretin receptors, and others.

The adhesion G protein-coupled receptors segment accounted for a significant revenue share in the market. This is due to their involvement in various physiological processes and diseases, which makes them a promising area for drug discovery. Additionally, they have unique activation mechanisms such as autoproteolysis and stalk exposure. These features offer multiple drug targeting possibilities and drive the segment growth.

• For instance, according to the data published by MedChemExpress, a company involved in offering research chemicals and biochemicals, adhesion G protein-coupled receptors play an important role in neural development, angiogenesis, cancer progression, and immune regulation.

Analysis by Application

By application, the market is divided into disease diagnosis, drug discovery & development, and others.

The drug discovery & development segment held a substantial share of the global G-protein coupled receptors market in 2024. The segment growth is attributed to the rise in drug discovery and development activities in GPCR, as it plays an important role in various physiological processes and is implicated in many diseases, such as cancer, diabetes, etc. Additionally, the increasing collaborations between operating players also support the market growth.

• For instance, in August 2022, Sosei Group Corporation and AbbVie entered into a license agreement and a new drug discovery collaboration for the discovery, development, and commercialization of small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with neurological disease.

Analysis by End-user

According to the end user segment, the market is classified into the pharmaceutical & biotechnology industry, academic & research institutes, and others. 

The pharmaceutical & biotechnology industry segment held a significant portion of the market. The growth of the segment is attributed to factors such as extensive research and development efforts by pharmaceutical companies, a significant increase in investments in drug discovery, and the high prevalence of GPCR-related diseases. Additionally, collaboration and partnerships between key operating players also support the segment's growth.

• For instance, in July 2024, Radionetics Oncology agreed with Eli Lilly and Company to continue work on Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals. As a part of a strategic agreement, Radionetics received a USD 140 million upfront cash payment.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for a substantial share of the global G-protein coupled receptors market in 2024. This is due to the strong presence of pharmaceutical and biotechnology industries, which are actively engaged in GPCR research and drug development. Additionally, increasing strategic initiatives such as collaboration agreements by key market players also supported the market growth in this region.

• For instance, in January 2025, Exicure, Inc., with GPCR Therapeutics, Inc., signed a Memorandum of Understanding (MOU). This agreement includes the acquisition of GPCR USA with technology transfer for the company's CXCR4 inhibitor.

Europe has a significant share of the global G-protein coupled receptors market. The growth of the region can be attributed to several factors, such as robust research infrastructure, significant investments in pharmaceutical and biotechnology R&D, and a large number of companies involved in GPCR-targeted drug development. Additionally, the well-established network of research institutions and universities also support the market growth in this region.

Asia Pacific is the fastest-growing region in the forecast years. The growing pharmaceutical industry and the rise in healthcare spending support the market growth in the region.

Key Players Covered

The global G-protein coupled receptors market is semi-consolidated, with a few key players having substantial market share. The report includes the profiles of the following key players:

• Thermo Fisher Scientific, Inc. (U.S.)
• Eurofins Scientific (Europe)
• Abcam plc. (U.K.)
• Enzo Biochem Inc. (U.S.)
• Merck KGaA (Germany)
• QIAGEN (Germany)
• Promega Corporation (U.S.)
• INDIGO Biosciences, Inc. (U.S.)
• Multispan (India)
• AFG Scientific (U.S.)

Key Industry Developments

• In June 2024, INDIGO Biosciences launched its latest cell-based GPCR assay. This assay is designed to activate or inhibit the Gastric Inhibitory Polypeptide Receptor (GIPR).
• In January 2021, PerkinElmer launched GPCR TR-FRET binding assay and Beta-Arrestin kits to help advance therapeutics discovery.